Use of pancreatic enzyme supplements for patients with cystic fibrosis in the context of fibrosing colonopathy. Consensus Committee.
about
Fibrosing colonopathy in cystic fibrosisPatterns of GI disease in adulthood associated with mutations in the CFTR genePathophysiology of cystic fibrosis and drugs used in associated digestive tract diseasesMaintenance of nutritional status in patients with cystic fibrosis: new and emerging therapiesColonic wall thickness measured by ultrasound: striking differences in patients with cystic fibrosis versus healthy controls.Pancreatic enzyme replacement therapy in cystic fibrosis: Australian guidelines. Pediatric Gastroenterological Society and the Dietitians Association of Australia.Efficacy and safety of a unique enteric-coated bicarbonate-buffered pancreatic enzyme replacement therapy in children and adults with cystic fibrosis.Efficacy and Safety of a New Formulation of Pancrelipase (Ultrase MT20) in the Treatment of Malabsorption in Exocrine Pancreatic Insufficiency in Cystic Fibrosis.Diagnosing malabsorption with systemic lipid profiling: pharmacokinetics of pentadecanoic acid and triheptadecanoic acid following oral administration in healthy subjects and subjects with cystic fibrosis.Is fibrosing colonopathy an immune mediated disease?Relation between dietary intake and nutritional status in cystic fibrosis.Colonic wall thickness, pancreatic enzyme dose and type of preparation in cystic fibrosis.Parental Depression and Pancreatic Enzymes Adherence in Children With Cystic FibrosisDelayed release pancrelipase for the treatment of pancreatic exocrine insufficiency associated with cystic fibrosis.Cystic fibrosis-related diabetes: from CFTR dysfunction to oxidative stress.Pancreatic enzyme products: digesting the changes.Cystic fibrosis: a clinician's tool for management of care advancing into the adult population.Malnutrition in cystic fibrosis: a review.Nutrition Management of Cystic Fibrosis in the 21st Century.Cystic fibrosis from the gastroenterologist's perspective.Treatment of Gastrointestinal Problems in Cystic Fibrosis.Practical guide to exocrine pancreatic insufficiency - Breaking the myths.In Vitro Comparison of Physical Parameters, Enzyme Activity, Acid Resistance, and pH Dissolution Characteristics of Enteric-Coated Pancreatic Enzyme Preparations: Implications for Clinical Variability and Pharmacy Substitution.Efficacy and safety of pancreatic enzyme replacement therapy on exocrine pancreatic insufficiency: a meta-analysis.Pancreatic Enzyme Replacement Therapy use in infants with Cystic Fibrosis Diagnosed by Newborn Screening.Diagnosis and management of pancreatic exocrine insufficiency (PEI) in primary care: consensus guidance of a Canadian expert panel.Update on intestinal strictures.Challenges in the management of pancreatic exocrine insufficiency
P2860
Q24553316-A606F502-1DFF-4F8F-8FEF-F815909595D9Q24673570-91A13CC7-5CFB-46E6-9884-9112E9D21E5CQ26825799-9234EFF4-FEEE-4AF2-9D16-AB677AFF0700Q26858964-EF4AC91E-49D1-4046-AC7F-2204A6D8FE0AQ33617918-04CA2900-EA4A-44F3-9661-847C1521958DQ33655567-3AF239B1-D756-478B-BFD1-E10985EA684AQ34149294-49FF4C9C-0D3C-4C91-A64F-72171D3BE854Q34416814-4E1C4FF0-608C-4B52-A63B-FDA9F910FE7FQ35148967-5A4C5A05-51D6-402F-90B0-FCC981199B3FQ35255967-50DF4147-6201-42FA-8729-974EC714367DQ35259561-EBFF15D9-FF8D-40C6-9DFD-20193DD1358DQ35261169-671EEBDF-8E97-4FF7-A2B7-69FC005F0A84Q36518770-5F08BB76-EF60-4496-A222-DFCC860B8F73Q37052832-44125387-477C-4D59-A7D2-C1E4EFB67789Q37470271-34367F52-0FB8-4526-9342-A0E4B6F145BCQ37871722-9D02507B-1AC9-441F-8857-A7FE05834916Q38054190-E5F95673-04A4-4E62-BD92-022DC18B63AFQ38156392-A1813C69-B0EE-4D67-B771-7B1BC2536CCFQ38538310-135F58E3-CDFB-4852-AFA1-764EB4078022Q38704228-71B46FE7-A3D9-4662-9EB6-9CC6C77EB666Q40564391-A947A8D5-AF7A-4EC1-BBB6-601CE6334888Q42322542-1B677B25-8D80-47EA-843E-613086592B01Q42535011-792A81AB-A698-4A1D-9745-E640B1A38216Q47132837-B101BF6B-5760-40DC-A989-775DA4CB7275Q47412357-145D7E17-4F9B-4545-95AE-51BB314990BDQ49554058-7250A450-A668-447B-85F9-E01AA9B2B61CQ52865173-F60D0557-4E0D-45A6-87FA-BE1BA81A595BQ58564354-2BD75B6F-A523-47DF-A5B0-ABAAD4327D55
P2860
Use of pancreatic enzyme supplements for patients with cystic fibrosis in the context of fibrosing colonopathy. Consensus Committee.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Use of pancreatic enzyme suppl ...... onopathy. Consensus Committee.
@en
type
label
Use of pancreatic enzyme suppl ...... onopathy. Consensus Committee.
@en
prefLabel
Use of pancreatic enzyme suppl ...... onopathy. Consensus Committee.
@en
P2093
P1476
Use of pancreatic enzyme suppl ...... onopathy. Consensus Committee.
@en
P2093
P304
P356
10.1016/S0022-3476(95)70153-2
P407
P577
1995-11-01T00:00:00Z